Evolución de la función renal en pacientes con úlcera de pie diabético tratados con Heberprot-P®
Year: 2022
Type: article
Abstract: Introduction: Diabetic foot ulcer represents a complication of diabetes mellitus. Heberprot-P® is a medicine for its treatment, whose active substance is a human growth factor that could be associated with the onset of kidney disease.Objective: To describe the evolution of renal function after treatment with Heberprot-P® in patients with diabetic foot ulcer.Methods: Prospective descriptive study in 90 patients diagnosed with diabetic foot ulcer treated with Heberprot-P®. The variables analyzed were: microalbuminuria, creatinine, uric acid and glomerular filtration, at baseline, 6 months and post-treatment year. Relative frequencies of qualitative variables were determined, and mean and standard deviation of quantitative variables. Friedman test for two independent samples, U Mann Whitney and Chi square independence test were performed.Results: The quantitative variables of renal function did not vary significantly. At baseline, the glomerular filtrate was 67.1 ml/min; and at both 6 months and a year, 67.2 ml/min. The mean creatinine at 6 months was 86.2 μmol/L; and after a year, 86.1 μmol/L. Uric acid increased its value from 331.7 mmol/L to 345.6 mmol/L at 6 months; and at 340 mmol/L after a year. Urinary albumin excretion improved significantly during the study.Conclusions: Patients with diabetic foot ulcer treated with Heberprot-P® showed no impairment of renal function during the first year of treatment. Urinary albumin excretion improved and the rest of the variables remained stable.
Language: Spanish
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7217002199